使用吻合夹(OTSC)对比标准治疗预防大消化性溃疡(尺寸≥1.5 cm)再出血:一项开放标签、国际多中心随机对照试验
这项国际多中心随机对照试验纳入溃疡尺寸≥1.5 cm的Forrest IIa级及以上消化性溃疡出血患者100例,比较OTSC与标准内镜治疗作为主要止血手段的疗效。在意向性治疗分析中,OTSC组30天再出血5/50(10%)与标准治疗组9/50(18%)无显著差异(p=0.23),全因死亡率亦无差异。结论认为常规使用OTSC作为大出血性消化性溃疡的主要止血方法并未显著降低30天再出血。
要点
- 在成功实现主要止血的患者中,OTSC组30天再出血2/46(4.35%)低于标准治疗组9/48(18.75%)(p=0.03)。
- 意向性治疗分析中,OTSC组30天再出血5/50(10%)与标准组9/50(18%)无显著差异(p=0.23)。
- 全因死亡率OTSC组2/50(4%)与标准组4/50(8%)无显著差异(p=0.68;OR=2.09,95%CI 0.37至11.95)。
核心结论
- 常规使用OTSC作为大出血性消化性溃疡的主要止血方法并未显著降低30天再出血。
研究设计与样本
- 这是一项2017年7月至2020年10月开展的国际多中心随机对照试验。
- 纳入溃疡尺寸≥1.5 cm且Forrest分级IIa级及以上的消化性溃疡出血患者。
- 共招募100例患者,OTSC组50例,标准治疗组50例。
- 主要结局为30天临床再出血。
- 样本量估算需100例患者,以80%把握度在0.05显著性水平(α)下采用双侧Z检验(合并)检测-0.15的差异。
主要发现
- 主要止血成功率OTSC组为46/50(92%),标准治疗组为48/50(96%)。
- 在主要止血成功的患者中,OTSC组30天再出血2/46(4.35%),标准治疗组9/48(18.75%)(p=0.03)。
- 意向性治疗分析中,30天再出血OTSC组5/50(10%)对比标准治疗组9/50(18%)(p=0.23)。
- 全因死亡率OTSC组2/50(4%)对比标准治疗组4/50(8%)(p=0.68;OR=2.09,95%CI 0.37至11.95)。
- 输血需求、住院时间、入住重症监护室及进一步干预方面两组均无差异。
临床怎么用
- 原文结论认为常规使用OTSC作为大出血性消化性溃疡的主要止血方法并未显著降低30天再出血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Over-the-scope clip (OTSC) has been used recently for primary haemostasis of peptic ulcers. This study aimed to compare the efficacy of OTSC to standard endoscopic therapy in primary treatment of patients with peptic ulcer bleeding that are of size ≥1.5 cm. The target population accounts for only 2.5% of all upper GI bleeders. METHODS: This was a multicentre international randomised controlled trial from July 2017 to October 2020. All patients with Forest IIa or above peptic ulcers of ≥1.5 cm were included. Primary outcome was 30-day clinical rebleeding. Secondary endpoints include 3-day all-cause mortality, transfusion requirement, hospital stay, technical and clinical success, and further interventions. 100 patients are needed to yield a power of 80% to detect a difference of -0.15 at the 0.05 significance level (alpha) using a two-sided Z-test (pooled). RESULTS: 100 patients were recruited. Success in achieving primary haemostasis was achieved in 46/50 (92%) and 48/50 (96%) in the OTSC and conventional arm, respectively. Among patients who had success in primary haemostasis, 2/46 (4.35%) patients in the OTSC arm and 9/48 (18.75%) patients in the conventional arm developed 30-day rebleeding (p=0.03). However, in an intention-to-treat analysis, there was no difference in rebleeding within 30 days (5/50 (10%) OTSC vs 9/50 (18%) standard, p=0.23) or all-cause mortality (2/50 (4%) OTSC vs 4/50 (8%) standard, p=0.68; OR=2.09, 95% CI 0.37 to 11.95). There was also no difference in transfusion requirement, hospital stay, intensive care unit admission and further interventions. CONCLUSION: The routine use of OTSC as primary haemostasis in large bleeding peptic ulcers was not associated with a significant decrease in 30-day rebleeding. TRIAL REGISTRATION NUMBER: NCT03160911.
引用
- Chan S, Pittayanon R, Wang HP, et al. Use of over-the-scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-labelled, multicentre international randomised controlled trial. Gut. 2022. PMID: 36307177. doi:10.1136/gutjnl-2022-327007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。